researcherstaffmalenoMichael J. CimaPhDMember of the Center for Assessment Technology and Continuous Health (CATCH)
Michael J. Cima, PhD
Michael J. Cima, PhD
Member of the Center for Assessment Technology and Continuous Health (CATCH)
About Michael J. Cima, PhD
Michael J. Cima, PhD is a Professor of Materials Science and Engineering at the Massachusetts Institute of Technology (MIT) and has an appointment at the Koch Institute for Integrative Cancer Research. He now holds the David H. Koch Professor of Engineering Chair at MIT. Prof. Cima is an author or co-author of over 250 peer reviewed scientific publications, 58 US patents and is a recognized expert in the field of materials processing. He is actively involved in materials and engineered systems for improvement in human health such as treatments for cancer, metabolic diseases and urological disorders.
Prof. Cima's research concerns advanced forming technology such as for complex macro and micro devices, colloid science, MEMS and other micro components for medical devices that are used for drug delivery and diagnostics, and high-throughput methods for formulations of materials and pharmaceutical formulations. He and his collaborators are developing implantable MEMS devices for unprecedented control in the delivery of pharmaceuticals and implantable diagnostic systems. He is currently the Director Convergence Products Research Laboratory and is Faculty Director of the Lemelson-MIT Program. His honors include election to the National Academy of Engineering in 2011. He is a co-inventor of MIT’s three dimensional printing process and is co-founder of MicroChips Inc., a developer of microelectronic based drug delivery and diagnostic systems. Prof. Cima took two sabbaticals to act as senior consultant and management team member at Transform Pharmaceuticals Inc., a company that he helped start and that was ultimately acquired by Johnson & Johnson Corporation. He is a Co-Founder and Director at T2 Biosystems, a medical diagnostics company and Taris Biomedical, a urology company.
CATCH is at the forefront of cultural change in medical research and practice.